Availability and Use of HIV Monitoring and Early Infant Diagnosis Technologies in WHO Member States in 2011–2013: Analysis of Annual Surveys at the Facility Level
Vincent Habiyambere and colleagues use annual surveys administered through WHO country offices to assess HIV testing coverage.
Vyšlo v časopise:
Availability and Use of HIV Monitoring and Early Infant Diagnosis Technologies in WHO Member States in 2011–2013: Analysis of Annual Surveys at the Facility Level. PLoS Med 13(8): e32767. doi:10.1371/journal.pmed.1002088
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002088
Souhrn
Vincent Habiyambere and colleagues use annual surveys administered through WHO country offices to assess HIV testing coverage.
Zdroje
1. Joint United Nations Programme on HIV/AIDS. Ambitious treatment targets: writing the final chapter of the AIDS epidemic. Geneva: UNAIDS; 2015. http://www.unaids.org/sites/default/files/media_asset/JC2670_UNAIDS_Treatment_Targets_en.pdf. Accessed 20 May 2016.
2. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf. Accessed 20 May 2016.
3. Joint United Nations Programme on HIV/AIDS. Diagnostic Access Initiative to achieve the 90-90-90 treatment targets. Geneva: UNAIDS; 2014. http://www.unaids.org/sites/default/files/media_asset/20150422_diagnostics_access_initiative.pdf. Accessed 20 May 2016.
4. Branson BM, Pandori M. 2012 HIV Diagnostics Conference: the molecular diagnostics perspective. Expert Rev Mol Diagn. 2013; 13(3): 243–5. doi: 10.1586/erm.13.5 23570401
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: WHO; 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed 20 May 2016.
6. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: WHO; 2014. http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/. Accessed 20 May 2016.
7. Desai D, Wu G, Zaman MH. Tackling HIV through robust diagnostics in the developing world: current status and future opportunities. Lab Chip. 2011; 11: 194–211. doi: 10.1039/c0lc00340a 21125097
8. Wong EY, Hewlett IK. HIV diagnostics: challenges and opportunities. HIV Therapy. 2013; 4: 399–412.
9. World Health Organization. The availability and use of HIV diagnostics: a 2012/2013 WHO survey in low- and middle-income countries. Geneva: WHO; 2014. http://www.who.int/hiv/pub/amds/amds-diagnostics-survey-dec2014/en/. Accessed 20 May 2016.
10. Joint United Nations Programme on HIV/AIDS.UNAIDS AIDSinfo Online Database. Geneva: UNAIDS; 2015. http://www.aidsinfoonline.org/devinfo/libraries/aspx/Home.aspx. Accessed 15 February, 2015.
11. Joint United Nations Programme on HIV/AIDS. UNAIDS Country reports. Geneva: UNAIDS; 2015. http://www.unaids.org/en/regionscountries/countries. Accessed 15 February, 2015
12. UNITAID. HIV/AIDS Diagnostics Technology Landscape. 4th Edition. Geneva: UNITAID; 2014. http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-HIV_Diagnostic_Landscape-4th_edition.pdf. Accessed 20 May 2016.
13. UNITAID. HIV/AIDS Diagnostics Technology Landscape. 5th Edition. Geneva: UNITAID; 2015. http://unitaid.org/images/marketdynamics/publications/UNITAID_HIV_Nov_2015_Dx_Landscape.PDF. Accessed 16 May, 2016.
14. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K, et al. Evaluation of the PIMA Point-of-Care CD4 Analyzer in VCT Clinics in Zimbabwe. JAIDS. 2010; 55(1): 1–7. doi: 10.1097/QAI.0b013e3181e93071 20622679
15. UNITAID. Murtagh MM. HIV/AIDS Diagnostic Landscape. 2nd Edition. Geneva: UNITAID; 2011. http://www.unitaid.eu/images/marketdynamics/publications/v2_hivdiagxlandscape.pdf. Accessed 01 April 2016.
16. Mercer. UK receives second lowest public holiday entitlement in the world. London: Mercer. Newsroom. 09 Sept 2014. http://www.mercer.com/newsroom/public-holiday-entitlements.html. Accessed 20 May 2016.
17. Rowley CF. Developments in CD4 and Viral Load Monitoring in Resource-Limited Settings. CID. 2014; 58: 407–12.
18. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc. 2012; 15: 17324. doi: 10.7448/IAS.15.2.17324 23078767
19. Médecins Sans Frontières. Getting to undetectable: usage of HIV viral load monitoring in five countries. MSF undetectable. Volume 5. Geneva: MSF Access Campaign; 2014; 5. https://www.msfaccess.org/sites/default/files/HIV_MSF_IssueBrief_Viral_Load_2014_b.pdf. Accessed 20 May 2016.
20. Médecins Sans Frontières. Achieving undetectable: what questions remain in scaling-up HIV virological treatment monitoring? MSF Undetectable. Volume 6. Geneva: MSF Access Campaign; 2014. https://www.msfaccess.org/sites/default/files/MSF_IssueBrief_undetectable6.pdf. Accessed 20 May 2016.
21. Aleku GA, Adoga MP, Agwale SM. HIV point-of-care diagnostics: meeting the special needs of sub-Saharan Africa. J Infect Dev Ctries. 2014; 8(10): 1231–43. doi: 10.3855/jidc.4664 25313598
22. Médecins Sans Frontières. Putting HIV and HCV to the test. A product guide for point-of-care CD4 and laboratory-based and point-of-care virological HIV and HCV tests. Geneva: MSF Access Campaign; 2015. http://msfaccess.org/HIV-HCV-diagnostic-product-guide-2015. Accessed 20 May 2016.
23. World Health Organization. List of prequalified in vitro diagnostic products. Geneva: WHO; 2016. http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/. Accessed 20 May 2016.
24. Schito ML, Peter TF, Cavanaugh S, Piatek AS, Young GJ, Alexander H, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis. 2012; 205(Suppl 2): S169–S180. http://jid.oxfordjournals.org/content/205/suppl_2/S169. Accessed 20 May 2016. doi: 10.1093/infdis/jis044 22457286
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2016 Číslo 8
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Význam hydratace při hojení ran
Najčítanejšie v tomto čísle
- Glycemic Control and the Risk of Tuberculosis: A Cohort Study
- Transitioning to Country Ownership of HIV Programs in Rwanda
- Dementia across the Lifespan and around the Globe—Pathophysiology, Prevention, Treatment, and Societal Impact: A Call for Papers
- Social Dancing and Incidence of Falls in Older Adults: A Cluster Randomised Controlled Trial